Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus-associated refractory cerebral vasculitis induces immune tolerance

Yalcin Mutlu M, Wacker J, Tascilar K, Taubmann J, Manger B, Krönke G, Schett G, Simon D (2022)

Publication Type: Journal article, Letter

Publication year: 2022

Journal

Rheumatology Oxford University Press

DOI: 10.1093/rheumatology/keac393

Authors with CRIS profile

Koray Tascilar Department of Medicine 3 – Rheumatology and Immunology Jule Taubmann Department of Medicine 3 – Rheumatology and Immunology Bernhard Manger Professur für Rheumatologie und Klinische Immunologie Gerhard Krönke Department of Medicine 3 – Rheumatology and Immunology Georg Schett Lehrstuhl für Innere Medizin III David Simon Department of Medicine 3 – Rheumatology and Immunology

How to cite

APA:

Yalcin Mutlu, M., Wacker, J., Tascilar, K., Taubmann, J., Manger, B., Krönke, G.,... Simon, D. (2022). Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus-associated refractory cerebral vasculitis induces immune tolerance. Rheumatology. https://doi.org/10.1093/rheumatology/keac393

MLA:

Yalcin Mutlu, Melek, et al. "Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus-associated refractory cerebral vasculitis induces immune tolerance." Rheumatology (2022).

BibTeX: Download